• Matheus De Silva Sewastjanow, Jane E Rogers, Wayne L Hofstetter, and Jaffer A Ajani.
• Department of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Tex.
• J. Thorac. Cardiovasc. Surg. 2023 Mar 1; 165 (3): 901905901-905.

AbstractThe CROSS trial group deserves enormous credit for completing a well-powered randomized trial that has established the CROSS strategy as a standard of care for patients with potentially resectable esophageal cancer. However, the 10-year results are rather disappointing with only 38% of all patients treated with the CROSS strategy cured compared with approximately 25% who had surgery alone. Another standard, perioperative chemotherapy has produced similar disappointing results as the CROSS strategy. Although many of us are consumed by the question as to which option is better for our patients, we conclude that both strategies produce only marginal benefits. We should have better treatment options. The timing may be opportune to reflect on how to develop novel and rational strategies rather than propagate the historical empiric approaches.Copyright © 2022 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

10 keywords...

hide…